Clinical trials: Cancer, Advanced Solid Tumors
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Solid Tumor
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an…
- Trial name
- NCT05162755
- Testing
- S095029, S95029 and Sym021
- Where
- 5 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Institut de Recherches Internationales Servier
Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
- Trial name
- NCT07612176
- Testing
- NEOK001, NEOK001 RDE
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- NEOK Bio, Inc.
Advanced Solid Tumors
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional…
- Trial name
- NCT05394350
- Testing
- MK-1088, Pembrolizumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Solid Tumour
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
There is a great need for new therapies for carcinomas that have progressed on or not responded to current therapy. There are no approved Met targeted agents in standard clinical use.
- Trial name
- NCT01721148
- Testing
- ASLAN002( BMS 777607)
- Volunteers
- 39 people
- Sponsor
- ASLAN Pharmaceuticals
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.
- Trial name
- NCT03389815
- Testing
- WX-0593 Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07387068
- Testing
- GEN1079
- Where
- 12 sites in United States, Spain
- Volunteers
- 121 people
- Sponsor
- Genmab
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
RATIONALE: A computer-based survey and communication aid may help physicians and patients to communicate better and help make treatment decisions easier.
- Trial name
- NCT00244868
- Testing
- counseling intervention, educational intervention
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Fox Chase Cancer Center
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT05791448
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
Advanced Solid Tumors
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors
- Trial name
- NCT05951608
- Testing
- AK127 in combination with AK112
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Akeso
Bladder Cancer, Renal Pelvis Cancer
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to test the safety of gemcitabine and cisplatin plus Everolimus (also called RAD001) at different dose levels.
- Conditions
- Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- NCT01182168
- Testing
- gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor
A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors
This study is a non-randomized, open, multiple administration and dose escalation phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetic/pharmacodynamics Characteristics of multiple oral administration of…
- Trial name
- NCT03844438
- Testing
- LPM3480226
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00019708
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor in Advanced Stage
Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Evaluation of pharmacokinetic profile of SPARC1028
- Trial name
- NCT01305512
- Testing
- SPARC1028
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Neoplasm Metastases, Hepatic Insufficiency
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
- Trial name
- NCT01273493
- Testing
- Trabectedin, Dexamethasone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors, Lymphomas
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
The purpose of this study was to determine the metabolism and elimination of 14C-lenvatinib in participants with advanced solid tumors or lymphomas, who were unsuitable for, or had failed, existing therapies.
- Trial name
- NCT02578316
- Testing
- Lenvatinib
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Unspecified Adult Solid Tumor, Protocol Specific
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006464
- Testing
- 7-hydroxystaurosporine, cisplatin
- Where
- 4 sites in United States
- Sponsor
- City of Hope Medical Center
Solid Tumors
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
The study will be an open label, multicenter, dose finding study. Depending on the tolerated dose up to 7 dose levels will be explored in this study, approximately 33 patients (21-54 depending on number of cohorts) may be…
- Trial name
- NCT00819221
- Testing
- AZD2281, liposomal doxorubicin
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Cancer
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT02752516
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
- Trial name
- NCT02900157
- Testing
- MEDI9090, Durvalumab
- Where
- 8 sites in United States, Japan
- Volunteers
- 42 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.